When employed in ACC diagnostics, PSMA-targeting radiopharmaceuticals showed a remarkably variable uptake (in terms of SUVmax) in the primary tumor, local recurrence, and distant metastases; however, it was higher than the background in most of the included investigations [14,15,16,17,18,19]. This evidence concerns the gene FOLH1 and adrenal cortex carcinoma.